BioSpace News Archive

Entos Pharmaceuticals, Inc. (Entos), a clinical-stage biotechnology company developing genetic medicines with its Fusogenix proteolipid vehicle (PLV) nucleic acid delivery platform, and BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that they have entered into an agreement that will see Entos apply its Fusogenix nucleic acid delivery technology to promising gene therapy candidates in the BioMarin pipeline.

Thermo Fisher Scientific Inc., the world leader in serving science, today announced innovative proteomics solutions and a series of co-marketing agreements with industry experts, advancing the throughput, comprehensiveness and quality of proteomics workflows for applications such as single-cell studies and translational research.

Akebia Therapeutics, Inc. today announced that John P. Butler , Chief Executive Officer, will present at the Jefferies London Healthcare Conference, which takes place November 16 – 19, 2021.

Nektar Therapeutics (NASDAQ: NKTR) today announced it has appointed Diana M. Brainard , M.D., as an independent director to its Board of Directors.

Rigel Pharmaceuticals, Inc. announced plans to exit early-stage research and focus resources on its mid to late-stage development programs and its commercial efforts.

The PINC AI™ Applied Sciences (PAS) team, a division of PINC AI, the technology and services platform of Premier, Inc. (NASDAQ: PINC), and Mölnlycke, a world-leading medical solutions company, today announced the initiation of a clinical trial to evaluate the value of hospital-wide patient bathing and the impact of specialized protocol training, education and compliance auditing on reducing hospital-acquired infections (HAIs).

Moderna, Inc. today announced positive data from the AstraZeneca-led Phase 2 (EPICCURE) study evaluating the use of an mRNA therapeutic that encodes for vascular endothelial growth factor-A (VEGF-A) (AZD8601) in patients undergoing coronary artery bypass grafting (CABG).

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has acquired Combangio, Inc., a private, clinical-stage company developing regenerative biotherapies for severe ocular surface diseases.

Following the announcement of positive clinical results in the groundbreaking OTO-313 Phase 1 trial for patients suffering from tinnitus, Light E.N.T. is pleased to announce that it is seeking volunteers for Phase 2 of OTO-313 trials.

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited (SK bioscience), a biotechnology company in South Korea, today announced the submission of a Biologics License Application (BLA) for Novavax’ COVID-19 vaccine to South Korea’s Ministry of Food and Drug Safety (MFDS).